Do Peptides Actually Work?

“Do peptides work?” is really several questions wearing one trench coat. Peptides aren’t a single ingredient — they’re a category covering dozens of distinct molecules with different jobs and, crucially, different amounts of evidence behind them. Answering the broad question honestly means breaking it down peptide by peptide rather than accepting or dismissing the whole category at once.

The penetration problem, properly

Before efficacy, there’s delivery. The 500-dalton rule suggests molecules above that size struggle to cross the stratum corneum, and amino acids average roughly 110–130 Daltons each, which puts a lot of common peptides right at the awkward edge:

• Dipeptides (2 amino acids, ~200–300 Da) — likely to penetrate
• Tripeptides (3 amino acids, ~300–400 Da) — likely to penetrate
• Tetrapeptides (~400–550 Da) — borderline
• Pentapeptides (~500–700 Da) — challenging
• Hexapeptides (~600–800 Da) — unlikely without formulation help

A fair few well-known skincare peptides sit at or above that threshold. That doesn’t automatically disqualify them — lipophilic modifications like the palmitoyl chain attached to palmitoyl pentapeptide-4 exist specifically to improve penetration — but it does mean any efficacy claim for a larger peptide needs to explain how the molecule is actually reaching its target, not just what it does once it gets there.

The evidence, peptide by peptide

Copper peptides (GHK-Cu) have the most robust research base of anything in this category — genuine wound-healing acceleration in clinical studies, and some evidence of improved skin thickness and collagen content in cosmetic use. Part of that comes down to size: at roughly 400 Daltons, GHK-Cu is small enough to plausibly penetrate, which is more than can be said for several bigger, more heavily marketed peptides. We’ve gone deeper on the mechanism, the cosmetic trial data, and its real limitations in a dedicated piece on copper peptides.

Matrixyl (palmitoyl pentapeptide-4) has several published studies showing increased collagen synthesis in cell culture and modest wrinkle improvements in human trials — one often-cited 2005 study reported wrinkle-depth improvements comparable to retinol over 12 weeks. Read that comparison with the same caveats you’d apply to any single, industry-adjacent trial: the human evidence for Matrixyl overall is limited in volume, frequently funded by companies with a commercial interest in the result, and the effect size, where it’s been measured, tends to be modest rather than dramatic. Promising, not proven at scale.

Argireline (acetyl hexapeptide-3) is where the claims most outrun the evidence. The “topical Botox” comparison doesn’t hold up mechanically: Botox works by injecting a neurotoxin directly into muscle to block nerve signals. For Argireline to do anything comparable, it would need to penetrate skin, reach nerve endings, and accumulate in a meaningful concentration — a much longer chain of ifs. In vitro studies show it can inhibit neurotransmitter release in cell cultures, but cell-culture results don’t reliably predict what happens on intact human skin. The handful of human studies show modest improvements in wrinkle appearance, and it’s genuinely unclear how much of that is the claimed mechanism versus ordinary hydration and formulation effects.

Everything else — the long tail of named peptides that show up in ingredient lists — varies enormously. Some have only in vitro data. Some have small, poorly controlled human trials. Some have no independent research at all, just manufacturer-sponsored claims. Absence of evidence isn’t evidence the ingredient doesn’t work, but it does mean you’re paying for a hypothesis rather than a result. If you want a primer on why sample size, funding source, and study type change how much weight a claim should carry, we’ve written about that separately.

The comparison problem

A 10% improvement in wrinkle depth over 12 weeks sounds meaningful until you ask what it’s being compared to. Against a basic moisturiser, that’s a real result. Against prescription tretinoin, which can produce improvements several times larger, it’s modest. A lot of peptide research skips the active-comparator step entirely — showing a peptide beats a placebo is useful, but it doesn’t tell you how it stacks up against ingredients with decades of research behind them. Retinoids remain the strongest-evidenced anti-ageing actives available; peptides, as a category, sit well behind that bar, with more variable quality between individual ingredients.

What peptides can realistically offer

Based on where the evidence actually sits: copper peptides look genuinely effective, particularly for wound healing and skin repair, with anti-ageing benefits that appear real if modest — this is the peptide with the best evidence-to-marketing ratio going. Established signal peptides like Matrixyl can offer modest anti-ageing support that complements a routine built around stronger actives, though they’re unlikely to transform skin on their own. Neurotransmitter-inhibiting peptides are oversold relative to what the research supports — plausible mechanism, thin real-world evidence. Novel or obscure peptides with no independent research deserve scepticism regardless of how the label reads.

Peptides generally work best as supporting players rather than headline actives — contributing gentle collagen support alongside retinoids and vitamin C rather than replacing either. For people who can’t tolerate retinoids — pregnancy, sensitivity, or otherwise — a well-chosen peptide serum is a milder alternative with correspondingly milder expected results, not an equivalent one.

Common questions

Which single peptide has the strongest evidence? Copper peptides (GHK-Cu), by a reasonable margin — see the full breakdown for what that evidence does and doesn’t show.

Is Argireline worth using? It’s not going to replace Botox or come close. If you’re using it as a mild, low-risk addition to a formula you already like, that’s reasonable; buying it specifically to avoid injectables is likely to disappoint.

Should I choose a peptide product over a retinoid? Not if you can tolerate retinoids — the evidence base is much stronger. Peptides make more sense as a complement, or as an alternative for people who genuinely can’t use retinoids.

Why do some peptides have almost no research? Formulating and testing a new peptide is expensive, and a lot of ingredients reach market on the strength of in vitro data and marketing rather than independent clinical trials. That’s a gap in evidence, not necessarily proof the ingredient fails.

The bottom line

Some peptides do, modestly, with real caveats about penetration and formulation quality. Copper peptides have genuine evidence behind them. Established signal peptides like Matrixyl show real if limited benefits. Neurotransmitter-inhibiting peptides are oversold relative to what’s been shown. Peptides aren’t the future of skincare — that title still belongs to prescription retinoids — but they’re not pure marketing fantasy either. They sit in the middle: genuinely active for some purposes, unremarkable for others, and worth calibrating your expectations to the specific peptide rather than the category as a whole.